DK2216021T3 - Farmaceutisk sammensætning til behandling af overaktiv blære - Google Patents

Farmaceutisk sammensætning til behandling af overaktiv blære

Info

Publication number: DK2216021T3
Authority: DK; Denmark
Prior art keywords: overactive; blower; treatment; pharmaceutical composition; pharmaceutical
Prior art date: 2007-11-02

Application number

DK08843784.3T

Other languages

English (en)

Inventor

Masanori Suzuki

Masashi Ukai

Akiyoshi Ohtake

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-02

Filing date

2008-10-30

Publication date

2012-11-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2216021(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-10-30 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2012-11-05 Application granted granted Critical

2012-11-05 Publication of DK2216021T3 publication Critical patent/DK2216021T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DK08843784.3T 2007-11-02 2008-10-30 Farmaceutisk sammensætning til behandling af overaktiv blære DK2216021T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007285802		2007-11-02
PCT/JP2008/069736 WO2009057685A1 (ja)	2007-11-02	2008-10-30	過活動膀胱治療用医薬組成物

Publications (1)

Publication Number	Publication Date
DK2216021T3 true DK2216021T3 (da)	2012-11-05

Family

ID=40591069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08843784.3T DK2216021T3 (da)	2007-11-02	2008-10-30	Farmaceutisk sammensætning til behandling af overaktiv blære

Country Status (12)

Country	Link
US (2)	US20100240697A1 (da)
EP (1)	EP2216021B1 (da)
JP (1)	JP5263170B2 (da)
CA (1)	CA2704298C (da)
CY (1)	CY1113670T1 (da)
DK (1)	DK2216021T3 (da)
ES (1)	ES2393525T3 (da)
HR (1)	HRP20121078T1 (da)
PL (1)	PL2216021T3 (da)
PT (1)	PT2216021E (da)
SI (1)	SI2216021T1 (da)
WO (1)	WO2009057685A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9522129B2 (en)	2010-08-03	2016-12-20	Velicept Therapeutics, Inc.	Pharmaceutical Combination
BR112013002511A2 (pt)	2010-08-03	2017-06-27	Altherx Inc	combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa
US9907767B2 (en)	2010-08-03	2018-03-06	Velicept Therapeutics, Inc.	Pharmaceutical compositions and the treatment of overactive bladder
AU2013309922A1 (en) *	2012-08-31	2015-04-09	Astellas Pharma Inc.	Orally administered medical composition
AU2015313221B2 (en) *	2014-09-09	2019-11-21	Cytokinetics Incorporated	Novel pharmaceutical composition for prevention and/or treatment of urinary incontinence
EP3226849A4 (en)	2014-12-03	2018-05-09	Velicept Therapeutics, Inc.	Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN108290824B (zh)	2015-10-23	2022-03-11	B3Ar治疗股份有限公司	索拉贝隆两性离子及其应用
EP3448367A1 (en)	2016-04-25	2019-03-06	Synthon BV	Tablets comprising mirabegron and solifenacin
US10543174B2 (en)	2016-04-25	2020-01-28	Synthon B.V.	Modified release tablet composition comprising mirabegron
CN117695286A (zh)	2017-06-06	2024-03-15	住友制药(苏州)有限公司	使用维贝隆以治疗膀胱过度活动症
US10478399B2 (en)	2017-10-12	2019-11-19	Synthon B.V.	Modified release tablet composition comprising mirabegron
US11583521B2 (en) *	2020-07-01	2023-02-21	Jubilant Pharma Holdings Inc.	Long-acting injection dosage form of beta 3 adrenoreceptor agonists
EP4159199A1 (en)	2021-09-29	2023-04-05	Lotus Pharmaceutical Co., Ltd.	Combined formulation of mirabegron and solifenacin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO2005012I1 (no) *	1994-12-28	2005-06-06	Debio Rech Pharma Sa	Triptorelin og farmasoytisk akseptable salter derav
KR100506568B1 (ko)	1997-10-17	2006-04-21	아스텔라스세이야쿠 가부시키가이샤	아미드유도체및이의염,및이를포함하는약제학적제제
US7342117B2 (en) *	2001-10-30	2008-03-11	Astellas Pharma Inc.	α-form or β-form crystal of acetanilide derivative
EP1552825A4 (en) *	2002-06-07	2009-11-25	Astellas Pharma Inc	THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
US7750029B2 (en) *	2002-11-07	2010-07-06	Astellas Pharma Inc.	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP1424079A1 (en)	2002-11-27	2004-06-02	Boehringer Ingelheim International GmbH	Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ATE365554T1 (de) *	2003-04-04	2007-07-15	Dynogen Pharmaceuticals Inc	Methode zur behandlung von erkrankungen der unteren harnwege
BRPI0416157A (pt) *	2003-11-03	2007-01-09	Boehringer Ingelheim Int	composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase
CA2560080A1 (en)	2004-03-16	2005-09-22	Astellas Pharma Inc.	Solifenacin-containing composition
JPWO2006090759A1 (ja) *	2005-02-25	2008-07-24	アステラス製薬株式会社	ソリフェナシン含有医薬
EP1967202A1 (en) *	2007-03-05	2008-09-10	AEterna Zentaris GmbH	Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity

2008
- 2008-10-30 DK DK08843784.3T patent/DK2216021T3/da active
- 2008-10-30 JP JP2009539100A patent/JP5263170B2/ja active Active
- 2008-10-30 WO PCT/JP2008/069736 patent/WO2009057685A1/ja active Application Filing
- 2008-10-30 US US12/740,699 patent/US20100240697A1/en not_active Abandoned
- 2008-10-30 SI SI200830841T patent/SI2216021T1/sl unknown
- 2008-10-30 EP EP08843784A patent/EP2216021B1/en not_active Revoked
- 2008-10-30 CA CA2704298A patent/CA2704298C/en active Active
- 2008-10-30 PL PL08843784T patent/PL2216021T3/pl unknown
- 2008-10-30 PT PT08843784T patent/PT2216021E/pt unknown
- 2008-10-30 ES ES08843784T patent/ES2393525T3/es active Active
2012
- 2012-12-28 HR HRP20121078AT patent/HRP20121078T1/hr unknown
2013
- 2013-01-04 CY CY20131100004T patent/CY1113670T1/el unknown
- 2013-01-24 US US13/748,956 patent/US8772315B2/en active Active

Also Published As

Publication number	Publication date
CY1113670T1 (el)	2016-06-22
SI2216021T1 (sl)	2013-01-31
EP2216021A4 (en)	2010-11-03
US20100240697A1 (en)	2010-09-23
US20130150402A1 (en)	2013-06-13
ES2393525T3 (es)	2012-12-26
EP2216021B1 (en)	2012-10-17
CA2704298A1 (en)	2009-05-07
US8772315B2 (en)	2014-07-08
WO2009057685A1 (ja)	2009-05-07
HRP20121078T1 (hr)	2013-01-31
JPWO2009057685A1 (ja)	2011-03-10
PT2216021E (pt)	2012-11-06
EP2216021A1 (en)	2010-08-11
JP5263170B2 (ja)	2013-08-14
CA2704298C (en)	2015-07-21
PL2216021T3 (pl)	2013-03-29

Publication	Publication Date	Title
LTPA2018014I1 (lt)	2018-12-10	Farmacinė kompozicija 514
DK2216021T3 (da)	2012-11-05	Farmaceutisk sammensætning til behandling af overaktiv blære
LTPA2018005I1 (lt)	2018-02-12	Farmacinė kompozicija
DK2474321T3 (da)	2019-06-03	Sammensætninger til behandling af collagenmedierede sygdomme
DK2154971T3 (da)	2012-04-02	Synergistisk farmaceutisk kombination til behandling af cancer
DK2478907T3 (da)	2021-05-25	Sammensætninger til behandling af kræft
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0721651A2 (pt)	2014-04-01	Composição farmacêutica
DK2220116T3 (da)	2012-11-26	Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2137537T3 (da)	2013-07-29	Sammensætninger og anvendelser til behandling af multipel sklerose
DK3354276T3 (da)	2020-03-30	Sammensætninger til behandlingen af gastrointestinal inflammation
DK2303330T4 (da)	2021-09-13	Farmaceutiske sammensætninger til behandling af parkinsons sygdom
DK1868579T3 (da)	2011-01-10	Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
DK2796469T3 (da)	2019-08-12	Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK3492069T3 (da)	2022-03-14	Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
BRPI0715712A2 (pt)	2014-06-24	Composição farmacêutica
DK2114386T3 (da)	2013-03-18	Farmaceutisk sammensætning til behandling af diabeteskomplikationer
BRPI0719393A2 (pt)	2015-03-31	Composição farmacêutica
DK2120884T3 (da)	2011-02-07	Farmaceutisk sammensætning
BRPI0716445A2 (pt)	2013-09-17	composiÇço farmacÊutica
DK2285413T3 (da)	2012-08-27	Farmaceutisk sammensætning
DK2209784T3 (da)	2012-10-29	Forbindelser til behandling af hepatitis C
DK2966175T3 (da)	2019-07-01	Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0921313A2 (pt)	2015-12-29	composição farmaucêutica